Sanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestones
|
HBM Healthcare Investments AG / Key word(s): Acquisition
HBM Healthcare Investments (SIX: HBMN) today announced that Dren Bio, a private portfolio company, and Sanofi have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 engages specific myeloid cells to induce deep B-cell depletion, with potential applications in patients with refractory B-cell-mediated autoimmune diseases such as lupus, where significant unmet medical needs remain. Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and make additional payments totaling up to $1.3 billion upon achievement of certain development and launch milestones. The companies expect the transaction to close during Q2 2025. Following the acquisition of Dren-0201, Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics for the treatment of cancer, autoimmune, and other serious diseases. HBM Healthcare Investments will continue to hold a stake of around 9 percent in Dren Bio. Based on our assessment of the transaction terms (upfront amount plus discounted potential milestone payments), the net asset value per HBM share will increase by CHF 8.70 (+3.6%) with a cash inflow of approximately USD 50 million for HBM Healthcare Investments from the upfront amount.
About Dren Bio Dren Bio (Foster City, CA, USA) is a privately held, clinical-stage biopharmaceutical company pioneering the discovery and development of novel antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents. For more information about Dren Bio and its current development pipeline, please visit http://www.drenbio.com/. Contact End of Inside Information |
| Language: | English |
| Company: | HBM Healthcare Investments AG |
| Bundesplatz 1 | |
| 6300 Zug | |
| Switzerland | |
| Phone: | +41438887171 |
| Fax: | +41438887172 |
| E-mail: | info@hbmhealthcare.com |
| Internet: | https://www.hbmhealthcare.com |
| ISIN: | CH0012627250 |
| Valor: | 1262725 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2103478 |
| End of Announcement | EQS News Service |
|
|
2103478 20-March-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.